Circulating and tumor-based biomarkers predict clinical activity in cancer patients treated with the engineered anti-PD-L1 antibody MPDL3280A. (6th November 2014) - Kowanetz, Marcin; Rabe, Christina; Xiao, Yuanyuan; Wu, Qun J; Koeppen, Hartmut; Leddy, Cecilia; Patel, Rajesh D; Powderly, John; Kohrt, Holbrook; Gettinger, Scott; Soria, Jean-Charles; Herbst, Roy S; et al.